Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jinlida for impaired glucose tolerance in metabolic syndrome
ChiCTR1900023241Phase 4Completed
- Sponsor
- Hebei Yiling Hospital
- Start
- Jun 2019
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of jinlida in prediabetes and cardiometabolic risk (CMR) (2 arms), sponsored by Hebei Yiling Hospital. Primary endpoint: Incidence of type 2 diabetes. Started Jun 2019; status: completed.
02
Drugs
jinlida
03
Conditions
prediabetescardiometabolic risk (CMR)
Beyond the preview
Go deeper on ChiCTR1900023241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900023241.